PL2625175T3 - Krystaliczny ((R)-(E)-2-(4-(2-(5-(1-(3,5-dichloropirydyn-4-ylo)etoksy)-1H-indazol-3-ilo)winylo)-1H-pirazol-1-ilo)etanol i jego zastosowanie jako inhibitora FGFR - Google Patents

Krystaliczny ((R)-(E)-2-(4-(2-(5-(1-(3,5-dichloropirydyn-4-ylo)etoksy)-1H-indazol-3-ilo)winylo)-1H-pirazol-1-ilo)etanol i jego zastosowanie jako inhibitora FGFR

Info

Publication number: PL2625175T3
Authority: PL; Poland
Prior art keywords: dichloropyridin; indazol; pyrazol; ethoxy; crystalline
Prior art date: 2010-10-05

Application number

PL11771312T

Other languages

English (en)

Inventor

Benjamin Alan Diseroad

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-10-05

Filing date

2011-09-29

Publication date

2016-04-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44999860&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2625175(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-09-29 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2016-04-29 Publication of PL2625175T3 publication Critical patent/PL2625175T3/pl

Links

GKJCVYLDJWTWQU-CXLRFSCWSA-N 2-[4-[(e)-2-[5-[(1r)-1-(3,5-dichloropyridin-4-yl)ethoxy]-1h-indazol-3-yl]ethenyl]pyrazol-1-yl]ethanol Chemical compound O([C@H](C)C=1C(=CN=CC=1Cl)Cl)C(C=C12)=CC=C1NN=C2\C=C\C=1C=NN(CCO)C=1 GKJCVYLDJWTWQU-CXLRFSCWSA-N 0.000 title 1
229940125829 fibroblast growth factor receptor inhibitor Drugs 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

PL11771312T 2010-10-05 2011-09-29 Krystaliczny ((R)-(E)-2-(4-(2-(5-(1-(3,5-dichloropirydyn-4-ylo)etoksy)-1H-indazol-3-ilo)winylo)-1H-pirazol-1-ilo)etanol i jego zastosowanie jako inhibitora FGFR PL2625175T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US38991110P	2010-10-05	2010-10-05
PCT/US2011/053798 WO2012047699A1 (en)	2010-10-05	2011-09-29	Crystalline (r) - (e) -2- (4- (2- (5- (1- (3, 5 -dichloropyridin-4 -yl) ethoxy) - 1h - indazol - 3 - yl) vinyl) -1 h- pyrazol- 1 -yl) ethanol and its use as fgfr inhibitor
EP11771312.3A EP2625175B1 (en)	2010-10-05	2011-09-29	Crystalline (r)-(e)-2-(4-(2-(5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1h-indazol-3-yl)vinyl)-1h-pyrazol-1-yl)ethanol and its use as fgfr inhibitor

Publications (1)

Publication Number	Publication Date
PL2625175T3 true PL2625175T3 (pl)	2016-04-29

Family

ID=44999860

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL11771312T PL2625175T3 (pl)	2010-10-05	2011-09-29	Krystaliczny ((R)-(E)-2-(4-(2-(5-(1-(3,5-dichloropirydyn-4-ylo)etoksy)-1H-indazol-3-ilo)winylo)-1H-pirazol-1-ilo)etanol i jego zastosowanie jako inhibitora FGFR

Country Status (35)

Country	Link
US (1)	US8530665B2 (pl)
EP (1)	EP2625175B1 (pl)
JP (1)	JP5940547B2 (pl)
KR (1)	KR101527661B1 (pl)
CN (1)	CN103153983B (pl)
AR (1)	AR083091A1 (pl)
AU (1)	AU2011312485B2 (pl)
BR (1)	BR112013006336A2 (pl)
CA (1)	CA2813329C (pl)
CL (1)	CL2013000884A1 (pl)
CO (1)	CO6710911A2 (pl)
DK (1)	DK2625175T3 (pl)
DO (1)	DOP2013000072A (pl)
EA (1)	EA021817B1 (pl)
EC (1)	ECSP13012539A (pl)
ES (1)	ES2558777T3 (pl)
HK (1)	HK1184147A1 (pl)
HR (1)	HRP20151299T1 (pl)
HU (1)	HUE026379T2 (pl)
IL (1)	IL224850A (pl)
JO (1)	JO3062B1 (pl)
MA (1)	MA34552B1 (pl)
ME (1)	ME02307B (pl)
MX (1)	MX2013003907A (pl)
NZ (1)	NZ608482A (pl)
PE (1)	PE20140252A1 (pl)
PL (1)	PL2625175T3 (pl)
PT (1)	PT2625175E (pl)
RS (1)	RS54457B1 (pl)
SG (1)	SG188286A1 (pl)
SI (1)	SI2625175T1 (pl)
TW (1)	TWI418554B (pl)
UA (1)	UA111725C2 (pl)
WO (1)	WO2012047699A1 (pl)
ZA (1)	ZA201301560B (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19945982A1 (de) *	1999-09-24	2001-03-29	Knoll Ag	Geschwindigkeitsbestimmte Partikel
US8754114B2 (en)	2010-12-22	2014-06-17	Incyte Corporation	Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
LT3176170T (lt)	2012-06-13	2019-04-25	Incyte Holdings Corporation	Pakeisti tricikliniai junginiai, kaip fgfr inhibitoriai
WO2014026125A1 (en)	2012-08-10	2014-02-13	Incyte Corporation	Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en)	2012-12-19	2016-02-23	Incyte Holdings Corporation	Fused pyrazoles as FGFR inhibitors
DK2986610T5 (en)	2013-04-19	2018-12-10	Incyte Holdings Corp	BICYCLIC HETEROCYCLES AS FGFR INHIBITORS
CN103819396B (zh) *	2014-02-26	2016-06-15	四川大学	一种手性的1-（3,5-二氯吡啶-4-基）-乙醇的合成方法
US10851105B2 (en)	2014-10-22	2020-12-01	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
CN107438607B (zh)	2015-02-20	2021-02-05	因赛特公司	作为fgfr抑制剂的双环杂环
MA41551A (fr)	2015-02-20	2017-12-26	Incyte Corp	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (en)	2015-02-20	2016-08-25	Incyte Corporation	Bicyclic heterocycles as fgfr4 inhibitors
AR111960A1 (es)	2017-05-26	2019-09-04	Incyte Corp	Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
WO2019213506A1 (en)	2018-05-04	2019-11-07	Incyte Corporation	Salts of an fgfr inhibitor
PE20210920A1 (es)	2018-05-04	2021-05-19	Incyte Corp	Formas solidas de un inhibidor de fgfr y procesos para prepararlas
WO2020185532A1 (en)	2019-03-08	2020-09-17	Incyte Corporation	Methods of treating cancer with an fgfr inhibitor
KR20210142154A (ko)	2019-03-21	2021-11-24	옹쎄오	암 치료를 위한 키나제 억제제와 조합된 dbait 분자
WO2021007269A1 (en)	2019-07-09	2021-01-14	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
KR20220100879A (ko)	2019-10-14	2022-07-18	인사이트 코포레이션	Fgfr 저해제로서의 이환식 헤테로사이클
WO2021076728A1 (en)	2019-10-16	2021-04-22	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
CA3159348A1 (en)	2019-11-08	2021-05-14	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
JP2023505258A (ja)	2019-12-04	2023-02-08	インサイト・コーポレイション	Ｆｇｆｒ阻害剤としての三環式複素環
PE20221504A1 (es)	2019-12-04	2022-09-30	Incyte Corp	Derivados de un inhibidor de fgfr
WO2021148581A1 (en)	2020-01-22	2021-07-29	Onxeo	Novel dbait molecule and its use
CN111705099B (zh) *	2020-07-01	2022-03-08	天津药明康德新药开发有限公司	一种(s)-1-(3,5-二氯吡啶-4-取代)乙醇的制备方法
JP2023553835A (ja) *	2020-12-17	2023-12-26	ブロッサムヒル・セラピューティクス・インコーポレイテッド	大環状化合物およびそれらの使用
US11939331B2 (en)	2021-06-09	2024-03-26	Incyte Corporation	Tricyclic heterocycles as FGFR inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6897231B2 (en) *	2000-07-31	2005-05-24	Signal Pharmaceuticals, Inc.	Indazole derivatives as JNK inhibitors and compositions and methods related thereto
AP1666A (en) *	2000-09-11	2006-09-29	Chiron Corp	Quinolinone derivatives as tyrosine kinase inhibitors.
TW200406385A (en)	2002-05-31	2004-05-01	Eisai Co Ltd	Pyrazole compound and pharmaceutical composition containing the same
BRPI0508895A (pt) *	2004-03-17	2007-09-11	Pfizer	formas polimorficas e amorfa de {2-flúor-5-[3-((e)-2-piridn-2-il-vinil)-1h-indazol-6-ilamin]- fenil}-amida de ácido 2,5-dimetil-2h-pirazol-3-carboxìlico
JP4746299B2 (ja) *	2004-07-16	2011-08-10	ジュズインターナショナルピーティーイーエルティーディー	金属酸化物粉末の製造方法
JP2006163651A (ja)	2004-12-03	2006-06-22	Sony Computer Entertainment Inc	表示装置、表示装置の制御方法、プログラム及びフォントデータ
US20060160863A1 (en) *	2005-01-05	2006-07-20	Agouron Pharmaceuticals, Inc.	Polymorphic and amorphous forms of 2-{3-[(E)-2-(4,6-dimethyl-pyridin-2-yl)-vinyl]-1H-indazol-6-ylamino}-N-(4-hydroxy-but-2-ynyl)benzamide
WO2007058626A1 (en)	2005-11-16	2007-05-24	S*Bio Pte Ltd	Indazole compounds
MX2009010761A (es) *	2007-04-05	2009-10-28	Pfizer Prod Inc	Formas cristalinas de 6-[2-(metilcarbamoil)fenilsulfanil]-3-e-[2-( piridin-2-il)etenil]indzol adecuadas para el tratamiento del crecimiento celular anormal en mamiferos.
JO2860B1 (en) *	2009-05-07	2015-03-15	ايلي ليلي اند كومباني	Phenylendazolyl compounds

2011
- 2011-09-22 JO JOP/2011/0294A patent/JO3062B1/ar active
- 2011-09-23 TW TW100134428A patent/TWI418554B/zh not_active IP Right Cessation
- 2011-09-23 AR ARP110103482A patent/AR083091A1/es unknown
- 2011-09-29 AU AU2011312485A patent/AU2011312485B2/en not_active Ceased
- 2011-09-29 KR KR1020137008655A patent/KR101527661B1/ko not_active IP Right Cessation
- 2011-09-29 EA EA201390275A patent/EA021817B1/ru not_active IP Right Cessation
- 2011-09-29 JP JP2013532838A patent/JP5940547B2/ja not_active Expired - Fee Related
- 2011-09-29 CN CN201180048148.7A patent/CN103153983B/zh not_active Expired - Fee Related
- 2011-09-29 PT PT117713123T patent/PT2625175E/pt unknown
- 2011-09-29 DK DK11771312.3T patent/DK2625175T3/en active
- 2011-09-29 EP EP11771312.3A patent/EP2625175B1/en active Active
- 2011-09-29 SG SG2013013743A patent/SG188286A1/en unknown
- 2011-09-29 ES ES11771312.3T patent/ES2558777T3/es active Active
- 2011-09-29 MA MA35780A patent/MA34552B1/fr unknown
- 2011-09-29 US US13/248,055 patent/US8530665B2/en not_active Expired - Fee Related
- 2011-09-29 BR BR112013006336A patent/BR112013006336A2/pt not_active IP Right Cessation
- 2011-09-29 PL PL11771312T patent/PL2625175T3/pl unknown
- 2011-09-29 UA UAA201303378A patent/UA111725C2/uk unknown
- 2011-09-29 RS RS20150828A patent/RS54457B1/en unknown
- 2011-09-29 CA CA2813329A patent/CA2813329C/en not_active Expired - Fee Related
- 2011-09-29 NZ NZ608482A patent/NZ608482A/en not_active IP Right Cessation
- 2011-09-29 ME MEP-2015-198A patent/ME02307B/me unknown
- 2011-09-29 HU HUE11771312A patent/HUE026379T2/en unknown
- 2011-09-29 PE PE2013000789A patent/PE20140252A1/es not_active Application Discontinuation
- 2011-09-29 SI SI201130673T patent/SI2625175T1/sl unknown
- 2011-09-29 WO PCT/US2011/053798 patent/WO2012047699A1/en active Application Filing
- 2011-09-29 MX MX2013003907A patent/MX2013003907A/es active IP Right Grant
2013
- 2013-02-21 IL IL224850A patent/IL224850A/en not_active IP Right Cessation
- 2013-02-28 ZA ZA2013/01560A patent/ZA201301560B/en unknown
- 2013-04-02 CL CL2013000884A patent/CL2013000884A1/es unknown
- 2013-04-02 DO DO2013000072A patent/DOP2013000072A/es unknown
- 2013-04-03 EC ECSP13012539 patent/ECSP13012539A/es unknown
- 2013-04-08 CO CO13090555A patent/CO6710911A2/es unknown
- 2013-10-15 HK HK13111594.2A patent/HK1184147A1/xx not_active IP Right Cessation
2015
- 2015-11-30 HR HRP20151299TT patent/HRP20151299T1/hr unknown

Also Published As

Publication number	Publication date
CN103153983B (zh)	2014-11-05
PE20140252A1 (es)	2014-03-12
CA2813329C (en)	2015-05-26
RS54457B1 (en)	2016-06-30
CO6710911A2 (es)	2013-07-15
US20120083511A1 (en)	2012-04-05
EP2625175A1 (en)	2013-08-14
CN103153983A (zh)	2013-06-12
KR20130052680A (ko)	2013-05-22
EP2625175B1 (en)	2015-11-18
SG188286A1 (en)	2013-04-30
AU2011312485A1 (en)	2013-03-07
AR083091A1 (es)	2013-01-30
JP5940547B2 (ja)	2016-06-29
AU2011312485B2 (en)	2014-09-04
ES2558777T3 (es)	2016-02-08
MX2013003907A (es)	2013-06-03
HK1184147A1 (en)	2014-01-17
SI2625175T1 (sl)	2016-01-29
DK2625175T3 (en)	2016-02-01
UA111725C2 (uk)	2016-06-10
EA021817B1 (ru)	2015-09-30
PT2625175E (pt)	2016-01-22
CL2013000884A1 (es)	2013-10-18
HRP20151299T1 (hr)	2016-01-01
DOP2013000072A (es)	2013-08-15
JO3062B1 (ar)	2017-03-15
WO2012047699A1 (en)	2012-04-12
JP2013538875A (ja)	2013-10-17
KR101527661B1 (ko)	2015-06-09
EA201390275A1 (ru)	2013-07-30
ECSP13012539A (es)	2013-06-28
HUE026379T2 (en)	2016-06-28
IL224850A (en)	2016-09-29
US8530665B2 (en)	2013-09-10
BR112013006336A2 (pt)	2019-09-24
NZ608482A (en)	2014-03-28
ME02307B (me)	2016-06-20
TWI418554B (zh)	2013-12-11
CA2813329A1 (en)	2012-04-12
TW201249826A (en)	2012-12-16
MA34552B1 (fr)	2013-09-02
ZA201301560B (en)	2014-08-27

Publication	Publication Date	Title
HK1184147A1 (en)	2014-01-17	Crystalline(r)-(e)-2-(4-(2-(5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1h- indazol-3-yl)vinyl)-1h-pyrazol-1-yl) ethanol and its use as fgfr inhibitor ((r)-(e)-2-(4-(2-(5-(1-(35--4-))-1h--3-) )-1h--1-) fgfr
HUS2000049I1 (hu)	2021-01-28	Kináz aktivitással rendelkezõ helyettesített imidazol származékok
HK1203959A1 (en)	2015-11-06	Method for the preparation of 4-[3-(4-cyclopropanecarbonyl- piperazine-1-carbonyl)-4-fluoro-benzyl -2h-phthalazin-1-one 1-()-4-[5-[(34--4--1-) -2-
RS52795B (en)	2013-10-31	VINYL INDAZOLIL UNITS
EP2346508A4 (en)	2012-04-18	HETEROCYCLIC INHIBITORS OF KINASES
ZA201001513B (en)	2010-10-27	5-(4-(Haloalkoxy) phenyl) pyrimidine-2-amine compounds and compositions as kinase inhibitors
IL209122A0 (en)	2011-01-31	Phenyl or pyridinyl substituted indazoles derivatives
ZA201100026B (en)	2012-04-25	4-(pyridin-4-yl)-1h-(1,3,5)triazin-2-one derivatives as gsk3-beta inhibitors for the treatment of neurodegenerative diseases
IL208467A0 (en)	2010-12-30	3,4-substituted piperidine derivatives as renin inhibitors
EP2300453A4 (en)	2012-03-21	3,4-SUBSTITUTED PIPERIDINE DERIVATIVES AS INHIBITORS OF THE REINE
PL2943488T3 (pl)	2018-09-28	Postacie soli megluminowej kwasu 2-((1r,4r)-4-(4-(5-(benzoksazol-2-iloamino)pirydyn-2-ylo)fenylo)cykloheksylo)octowego i ich zastosowania jako inhibitory dgat1
TN2013000142A1 (en)	2014-06-25	Crystalline (r) - (e) -2- (4- (2- (5- (1- (3, 5 -dichloropyridin-4 -yl) ethoxy) - 1h - indazol - 3 - yl) vinyl) -1 h- pyrazol- 1 -yl) ethanol and its use as fgfr inhibitor
WO2011084652A3 (en)	2011-09-09	Crystalline salts of a factor xa inhibitor
BRPI0816757A2 (pt)	2015-03-17	Formas polimorfas de (s) -2- ((4-benzofuranil) carbonilaminometil)-1-((4-(2-metil-5-(4-fluorofenil))tia zolil)carbonil) piperidina
TH115254B (th)	2012-07-31	สารประกอบไวนิลอินดาโซลอิล
TH132151A (th)	2014-03-28	((r)-(e)-2-(4-(2-(5-(1-(3,5-ไดคลอโรไพริดิน-4-อิล)เอทธอกซี)-1h-อินดาซอล-3-อิล)ไวนิล)-1h-ไพราซอล-1-อิล)เอทธานอลเชิงผลึก
CY1117146T1 (el)	2017-04-05	Κρυσταλλικη (r)-(ε)-2-(4-(2-(5-(1-(3,5-διχλωροπυριδινο-4-υλ)αιθοξυ)-1 η-ινδαζολο-3-υλ)βινυλο)-1 η-πυραζολο-1-υλ)αιθανολη και η χρηση της ως αναστολεα του fgfr
ZA201007486B (en)	2011-12-28	3,4- substituted piperidine derivatives as renin inhibitors